| Ytd | 253.85% | |
| 1y | 594.79% |
| Open | 13.32 | Prev Close | 13.21 | Low | 12.94 | High | 13.67 | Mkt Cap | 2.69B |
| Vol | 7.43M | Avg Vol | 8.41M | EPS | -0.22 | P/E | N/A | Forward P/E | -133.40 |
| Beta | 2.48 | Short Ratio | 8.90 | Inst. Own | 36.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 12.34 | 200-d Avg | 6.50 | 1yr Est | 32.50 |
Short seller BMF Capital disclosed a short position in SELLAS Life Sciences, arguing the market has
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a lo
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) stock is trading higher on Thursday. Year-to-date, the
SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 pre
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.05) per share which missed the